Medical factors affecting patency of arteriovenous access

2002 Feldman, 1996, Complications of vascular access are associated with 20% of all hospitalizations. Hemodialysis access morbidity, J Am Soc Nephrol, 7, 523, 10.1681/ASN.V74523 Roselaar, 1995, Detection of oxidants in uremic plasma by electron spin resonance spectroscopy, Kidney Int, 48, 199, 10.1038/ki.1995.285 Descamps-Latscha, 1991, establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemolyzed patients, Nephron, 59, 279, 10.1159/000186565 Toborek, 1992, Effects of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure, Metabolism, 41, 1229, 10.1016/0026-0495(92)90014-2 Himmelfarb, 1993, Intradialytic granulocyte reactive oxygen species production, J Am Soc Nephrol, 4, 178, 10.1681/ASN.V42178 Weiss, 2001, Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access, Am J Kidney Dis, 37, 970, 10.1016/S0272-6386(05)80013-7 Masood, 1997, Endothelin-1 is a mediator of intimal hyperplasia in organ culture of human saphenous vein, Br J Surg, 84, 499, 10.1002/bjs.1800840418 Wilkie, 1992, Does the arteriovenous fistula in chronic hemodialysis patients stimulate endothelin-1 release?, Nephrol Dial Transplant, 7, 1019 Chuang, 2003, Significance of platelet activation in vascular access survival of haemodialysis patients, Nephrol Dial Transplant, 18, 947, 10.1093/ndt/gfg056 Domoto, 1991, Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis, Thromb Res, 62, 737, 10.1016/0049-3848(91)90377-9 Swedberg, 1989, Intimal fibromuscular hyperplasia at the venous anastamosis of PTFE grafts in hemodialysis patients, Circulation, 80, 1726, 10.1161/01.CIR.80.6.1726 Mattana, 1997, Leukocyte-polytetrafluorethylene interaction enhances proliferation of vascular smooth muscle cells via tumor necrosis factor-α secretion, Kidney Int, 52, 1478, 10.1038/ki.1997.478 Ejerblad, 1979, Arterial lesions of the radial artery in uremic patients, Acta Chir Scand, 145, 415 Kim, 2003, Preexisting intimal hyperplasia of radial artery is associated with early failure of radiocephalic arteriovenous fistula in hemodialysis patients, Am J Kidney Dis, 41, 422, 10.1053/ajkd.2003.50051 Olsson, 2001, Evidence of calcium phosphate depositions in stenotic arteriovenous fistulas, Am J Kidney Dis, 38, 377, 10.1053/ajkd.2001.26104 Conlon, 2000, Vascular access for hemodialysis, 86 Barth, 2003, Characteristics of hypotension-prone haemodialysis patients, Nephrol Dial Transplant, 18, 1353, 10.1093/ndt/gfg171 Windus, 1994, The effect of comorbid conditions on hemodialysis access patency, Adv Ren Replace Ther, 1, 148, 10.1016/S1073-4449(12)80045-8 Miller, 2000, Natural history of arteriovenous graft in hemodialysis patients, Am J Kidney Dis, 36, 68, 10.1053/ajkd.2000.8269 McCully, 1969, Vascular pathology of homocysteinemia, Am J Pathol, 56, 111 Taylor, 1999, Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease, J Vasc Surg, 29, 8, 10.1016/S0741-5214(99)70345-9 den Heijer, 1996, Hyperhomocysteinemia as a risk factor for deep-vein thrombosis, N Engl J Med, 334, 759, 10.1056/NEJM199603213341203 Finkelstein, 2001, Regulation of homocysteine metabolism, 92 Cook, 2002, Homocysteine and arterial disease. experimental mechanisms, Vascul Pharmacol, 38, 293, 10.1016/S1537-1891(02)00254-9 McCully, 1996, Homocysteine and vascular disease, Nat Med, 2, 386, 10.1038/nm0496-386 Rajkumar, 1999, Enhanced platelet aggregation, high homocysteine level, and microvascular disease in diabetic muscle infarctions, Endocr J UK, 11, 57, 10.1385/ENDO:11:1:57 Fukasawa, 2003, The methylenetetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients, Am J Kidney Dis, 41, 637, 10.1053/ajkd.2003.50125 Manns, 1999, Hyperhomocysteinemia, anticardiolipin status, and risk for vascular access thrombosis in hemodialysis patients, Kidney Int, 55, 315, 10.1046/j.1523-1755.1999.00258.x Hojs, 2002, Homocysteine and vascular access thrombosis in hemodialysis patients, Ren Fail, 24, 215, 10.1081/JDI-120004098 Sirrs, 1999, Homocysteine and vascular access complications in hemodialysis patients, Nephrol Dial Transplant, 14, 738, 10.1093/ndt/14.3.738 Shemin, 1999, Plasma total homocysteine and hemodialysis access thrombosis, J Am Soc Nephrol, 10, 1095, 10.1681/ASN.V1051095 Carmody, 1999, Folic acid inhibits homocysteine-induced proliferation of human arterial smooth muscle cells, J Vasc Surg, 30, 1121, 10.1016/S0741-5214(99)70053-4 Spence, 1999, Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients, Am J Nephrol, 19, 405, 10.1159/000013486 Hong, 1998, Plasma homocysteine, vitamin b6, vitamin b12 and folic acid in end-stage renal disease during low-dose supplementation with folic acid, Am J Nephrol, 18, 367, 10.1159/000013378 Wilcken, 1998, Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency, Metabolism, 37, 697, 10.1016/0026-0495(88)90093-5 Thambyrajah, 2000, Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?, Circulation, 102, 871, 10.1161/01.CIR.102.8.871 Bostom, 1996, High dose B vitamin treatment of hyperhomocysteinemia in dialysis patients, Kidney Int, 49, 147, 10.1038/ki.1996.19 Sunder-Plassmann, 2000, Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients, J Am Soc Nephrol, 11, 1106, 10.1681/ASN.V1161106 Dierkes, 1999, Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease, Clin Nephrol, 51, 108 Bostom, 2000, Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients, Circulation 2000, 101, 2829 Yango, 2001, L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients, Kidney Int, 59, 324, 10.1046/j.1523-1755.2001.00507.x Hauser, 2001, Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients, Am J Kidney Dis, 37, 758, 10.1016/S0272-6386(01)80125-6 Garcia-Martin, 1991, Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease, Nephrol Dial Transplant, 6, 543, 10.1093/ndt/6.8.543 Grönhagen-Riska, 1990, Raised concentrations of antibodies to cardiolipin in patients receiving dialysis, BMJ, 300, 1696, 10.1136/bmj.300.6741.1696 Haviv, 2000, Association of anticardiolipin antibodies with vascular access occlusion in hemodialysis patients, Nephron, 86, 447, 10.1159/000045833 Brunet, 1995, Antiphospholipids in hemodialysis patients, Kidney Int, 48, 794, 10.1038/ki.1995.352 Prakash, 1995, Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis, Am J Kidney Dis, 26, 347, 10.1016/0272-6386(95)90656-8 Schaeffer, 1994, Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial, JAMA, 271, 999, 10.1001/jama.1994.03510370051031 Cressman, 1992, Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients, Circulation, 86, 475, 10.1161/01.CIR.86.2.475 Goldwasser, 1994, Correlates of vascular access occlusion in hemodialysis, Am J Kidney Dis, 24, 785, 10.1016/S0272-6386(12)80672-X Astor, 2002, Race-specific association of lipoprotein(a) with vascular access interventions in hemodialysis patients, Kidney Int, 61, 1115, 10.1046/j.1523-1755.2002.00194.x Fodinger, 1996, Resistance to activated protein C (APC), Nephrol Dial Transplant, 11, 668, 10.1093/oxfordjournals.ndt.a027357 Sampram, 2001, The impact of factor V mutation on the risk for occlusion in patients undergoing peripheral vascular reconstructions, Eur J Vasc Endovasc Surg, 22, 134, 10.1053/ejvs.2001.1420 Murphy, 2000, Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy, Arterioscler Thromb Vasc Biol, 20, 266, 10.1161/01.ATV.20.1.266 Irish, 1997, The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients, Transplantation, 64, 604, 10.1097/00007890-199708270-00010 LeSar, 1999, Thrombotic complications resulting from hypercoaguable states in chronic hemodialysis, J Am Coll Surg, 189, 73, 10.1016/S1072-7515(99)00086-1 Diskin, 1993, Pharmacologic intervention to prevent hemodialysis vascular access thrombosis, Nephron, 64, 1, 10.1159/000187272 Rayner, 2003, Creation, cannulation and survival of arteriovenous fistulae, Kidney Int, 63, 323, 10.1046/j.1523-1755.2003.00724.x Avorn, 2002, Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure, J Clin Epidemiol, 55, 711, 10.1016/S0895-4356(02)00415-8 Goransson, 2001, Consequences of late referral of patients with end-stage renal disease, J Intern Med, 250, 154, 10.1046/j.1365-2796.2001.00869.x Chesser, 1999, Temporary vascular access for first dialysis is common, undesirable and usually avoidable, Clin Nephrol, 51, 228 Kudva, 1997, Management of infectious and cutaneous complications in vascular access, Semin Vasc Surg, 10, 184 Saeed Abdulrahman, 2002, A prospective study of hemodialysis access-related bacterial infections, J Infect Chemother, 8, 242, 10.1007/s10156-002-0184-8 Lentino, 2000, Staphylococcus aureus and other bacteremias in hemodialysis patients, Infection, 28, 355, 10.1007/s150100070005 Brock, 1992, The influence of human immunodeficiency virus infection and intravenous drug abuse on complications of hemodialysis access surgery, J Vasc Surg, 16, 904, 10.1016/0741-5214(92)90053-B Wetzig, 1985, One hundred cases of arteriovenous fistula for haemodialysis access, Aust N Z J Surg, 55, 551, 10.1111/j.1445-2197.1985.tb00943.x Ravani, 2002, Vascular access surgery managed by renal physicians, Am J Kidney Dis, 40, 1264, 10.1053/ajkd.2002.36897 Puskar, 2002, Survival of primary arteriovenous fistula in 463 patients on chronic hemodialysis, Croat Med J, 43, 306 Hodges, 1997, Longitudinal comparison of dialysis access methods, J Vasc Surg, 26, 1009, 10.1016/S0741-5214(97)70014-4 Leaf, 2003, Isometric exercise increases the size of forearm veins in patients with chronic renal failure, Am J Med Sci, 325, 115, 10.1097/00000441-200303000-00003 Saran, 2002, Association between vascular access failure and the use of specific drugs, Am J Kidney Dis, 40, 1255, 10.1053/ajkd.2002.36895 Sreedhara, 1994, Anti-platelet therapy in graft thrombosis, Kidney Int, 45, 1477, 10.1038/ki.1994.192 Taber, 1995, Maintenance of adequate hemodialysis access. Prevention of neointimal hyperplasia, ASAIO J, 41, 842, 10.1097/00002480-199510000-00005 Huang, 2001, Calcium channel antagonist verapamil inhibits neointimal formation and enhances apoptosis in a vascular graft model, Am J Surg, 181, 492, 10.1016/S0002-9610(01)00615-8 1990, Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis, BMJ, 300, 573, 10.1136/bmj.300.6724.573 DeMarchi, 1997, Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients, J Am Soc Nephrol, 8, 1147, 10.1681/ASN.V871147 Churchill, 1994, Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin, J Am Soc Nephrol, 4, 1809, 10.1681/ASN.V4101809